04 Sep 2009
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company (the “Company”), announces that on September 3, 2009 it was notified by Mr Angus Russell, Chief Executive Officer of the Company, of a sale on the same day of 17,219 Shire plc ordinary shares of £0.05 each (“Shares”). The Shares were sold at a price of £10.29 per Share.
Following this transaction, Mr Russell holds 96,331 Shares in the Company. He also retains an option over 554,760 Shares, Stock Appreciation Rights over 750,164 Shares and Performance Shares Awards over 458,095 Shares.
This notification is to satisfy the Company's obligations under 3.1.4(R)(1)(a)of the Disclosure and Transparency Rules.
For further information please contact:
Cléa Rosenfeld (Rest of the World) +44 1256 894 160
Eric Rojas (North America) +1 617 551 9715
Notes to editors
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.